FDA Brief

Warning letters Drugs

FDA warning letter to

AnuMed International, LLC

High riskIssued Aug 20, 2024Posted Aug 27, 2024Center for Drug Evaluation and Research (CDER)

FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.

What happened

FDA inspected AnuMed International's drug manufacturing facility in Phoenix, Arizona, from November 1 to 7, 2023, and reviewed the company website in February and April 2024. FDA found many products marketed with claims to treat, cure, or prevent disease without approved drug applications, plus labeling that misleadingly suggested FDA approval or registration. FDA also found CGMP (current good manufacturing practice) violations, including no identity testing of glycerin and ethyl alcohol lots and no adequate process validation or water system qualification.

What FDA found

  1. The company sold many products as drugs to treat or prevent disease without FDA-approved applications.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. Labels and websites suggested FDA approval or endorsement by claiming an 'FDA APPROVED FACILITY' or 'FDA registered facility.'

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  3. Some products lacked adequate directions for safe use by a layperson because they were for diseases needing a licensed practitioner.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)
  4. The firm did not test each incoming lot of glycerin and ethyl alcohol for identity and relied on supplier certificates.

    21 CFR 211.84(d)(1)
  5. The firm did not validate manufacturing processes or have adequate written production and process control procedures.

    21 CFR 211.100(a)
  6. The firm did not adequately qualify or monitor its purified water system used in manufacturing.

What FDA wants

FDA tells AnuMed to correct the violations and to provide component test results no later than 30 calendar days from the letter date, including tests of glycerin and alcohol for methanol or DEG/EG (diethylene glycol/ethylene glycol) contamination. It also asks for a risk assessment of products still within expiration and recalls or customer notifications if contaminated lots are found.

Who should pay attention

  • brands or clinics buying hormone creams from manufacturers
  • retailers and online marketplaces selling AnuMed products
  • drug makers that rely on supplier certificates for glycerin or alcohol

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk